Key Highlights

  • Shares are up 2.87% pre-market to $86.52, building on last week's roughly 7-12% surge.
  • The rally follows a legal Patent win and strong early Demand for the company's new Atera platform, with 2026 Revenue guidance raised to $610 million to $630 million.
  • The stock is pushing to fresh 52-week highs, aided by a wave of bullish analyst resets.

10x Genomics (NASDAQ:TXG) shares are up 2.87% pre-market to $86.52, building on last week's roughly 7-12% surge, as investors continue to digest a legal patent win, strong early demand for the company's new Atera platform, and momentum from raised full-year 2026 revenue guidance of $610 million to $630 million. The stock is pushing to fresh 52-week highs near $86, aided by a wave of bullish analyst resets, including UBS lifting its target to $68 from $20, and renewed enthusiasm around AI-enabled genomics tools.

The rally comes even as the underlying Business remains unprofitable, with second-quarter revenue down 12.6% year-over-year and continued operating losses. The company's core Chromium platform enables single-cell gene expression, immune profiling, and multiome analyses, while its Visium and Xenium platforms provide spatial gene expression and protein co-detection capabilities, serving academic, government, biopharmaceutical, and biotechnology customers globally.

Analyst Sentiment Shifts Sharply Higher

The scale of the recent analyst price-target increases stands out against the stock's underlying financial picture, suggesting the market is pricing in a turnaround narrative built around the new Atera platform and AI-enabled genomics demand rather than near-term profitability. Founded in 2012 and headquartered in Pleasanton, California, the company has established itself as a leading provider of tools for single-cell and spatial biology research.